Colombia National Porphyria Registry

Rare Diseases Clinical Trial

Official title: Colombia National Porphyria Registry

Status Active, not recruiting

Clinical Trial Summary

porphyria is classified as a rare disease and is produced by defects in the enzymatic activity in the biosynthesis of the heme group that leads to the over-accumulation and excretion of porphyrin precursors in hepatocytes or erythroid cells, extrahepatic or extramedullary cells, tissue, and end-organ injury. Acute intermittent porphyria is the most common and severe form of hepatic porphyria, with an annual incidence of symptomatic patients of 0.13 per million people. Aim: characterization of cases of acute hepatic porphyria in Colombia. Methods: a descriptive pilot study of patients diagnosed with acute hepatic porphyria's in Colombia. Patients of all age groups with a confirmed diagnosis of acute hepatic porphyria. Patients with concomitant pathologies, as well as pregnant women, will also be included. Patients who refuse to participate in the study will be excluded. Expected results: describe the sociodemographic and clinical characteristics of patients with a diagnosis of acute hepatic porphyria, and encourage patients and/or representatives in the research agenda.

Clinical Trial Description

A cross-sectional descriptive observational study is carried out in adult patients diagnosed with HAP in Colombia, the incidence and prevalence were estimated, the clinical, socio-demographic and acute attack characteristics are described, and the health-related quality of life was evaluated with the SF-36 questionnaire. ;

Related Conditions & MeSH terms

• Porphyria, Erythropoietic
• Porphyrias
• Rare Diseases

• NCT number: NCT05496933
• Study type: Observational [Patient Registry]
• Source: Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia
• Status: Active, not recruiting
• Start date: April 1, 2021
• Completion date: December 30, 2022